Literature DB >> 30713897

Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson's Disease?

Atbin Djamshidian1,2, Sabine Bernschneider-Reif3, Werner Poewe2, Andrew J Lees1.   

Abstract

Banisteriopsis caapi, a liana indigenous to the Amazon basin with metagnomigenic properties and possible anti-depressant effects is one of the natural sources of harmala alkaloids. A summary of early trials with extracts of Banisteriopsis caapi and Peganum harmala (from which harmine was first isolated) in the 1920s and 1930s on various forms of parkinsonism is given as well as a brief overview of the known pharmacological properties of harmine. Despite its earlier abandonment because of perceived weaker efficacy than solanaceous alkaloids like scopolamine and hyoscine we propose that harmine should be reconsidered as a potential rapidly acting anti-Parkinsonian agent.

Entities:  

Keywords:  Banisteriopsis caapi; Parkinson's disease; harmine

Year:  2015        PMID: 30713897      PMCID: PMC6353393          DOI: 10.1002/mdc3.12242

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  39 in total

1.  The pathogenesis of Parkinson's disease: a new hypothesis.

Authors:  A BARBEAU
Journal:  Can Med Assoc J       Date:  1962-10-13       Impact factor: 8.262

2.  Psychotomimetics, clinical and theoretical considerations: harmine, Win-2299 and nalline.

Authors:  H H PENNES; P H HOCH
Journal:  Am J Psychiatry       Date:  1957-04       Impact factor: 18.112

3.  Moclobemide and the risk of serotonin toxicity (or serotonin syndrome).

Authors:  Ken Gillman
Journal:  CNS Drug Rev       Date:  2004

4.  Apomorphine in Parkinson's disease.

Authors:  R S SCHWAB; L V AMADOR; J Y LETTVIN
Journal:  Trans Am Neurol Assoc       Date:  1951

5.  Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications.

Authors:  Fredricka C Martin; Anh Thu Le; Adrian Handforth
Journal:  Mov Disord       Date:  2005-03       Impact factor: 10.338

6.  [Distribution of 5-hydroxytryptamine (serotonin) in the human brain and its behavior in patients with Parkinson's syndrome].

Authors:  H BERNHEIMER; W BIRKMAYER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1961-10-15

7.  Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism.

Authors:  M J Schwarz; P J Houghton; S Rose; P Jenner; A D Lees
Journal:  Pharmacol Biochem Behav       Date:  2003-06       Impact factor: 3.533

8.  ADMINISTRATION OF DIHYDROXYPHENYLALANINE TO PARKINSONIAN PATIENTS.

Authors:  P L MCGEER; L R ZELDOWICZ
Journal:  Can Med Assoc J       Date:  1964-02-15       Impact factor: 8.262

9.  Elevation of blood beta-carboline alkaloids in essential tremor.

Authors:  E D Louis; W Zheng; E C Jurewicz; D Watner; J Chen; P Factor-Litvak; M Parides
Journal:  Neurology       Date:  2002-12-24       Impact factor: 9.910

Review 10.  Subcutaneously administered apomorphine: pharmacokinetics and metabolism.

Authors:  Peter A LeWitt
Journal:  Neurology       Date:  2004-03-23       Impact factor: 9.910

View more
  1 in total

1.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.